LA TERAPIA DELL'INFEZIONE NEONATALE DA STREPTOCOCCO BETA-EMOLITICO DI GRUPPO B

Translated title of the contribution: Treatment of group B streptococcus neonatal septicemia

A. Aabas, M. Berzioli, P. Brisotto, P. Caliandro, G. Chirico, F. Colonna, V. Curro, B. De Mitri, U. De Vonderweid, A. Del Prete, R. Giorgi, G. Latini, F. Morandi, C. Passerini, L. Quartulli, E. Rosati, A. Taborelli, E. Visona, R. Zanini

Research output: Contribution to journalArticlepeer-review

Abstract

Expectant therapy for early Group B Streptococcus onset septicemia must provide coverage against other microrganisms, such as L. Monocytogenes, H. Influenzae and S. Pneumoniae. It is possible to administer a combination of antimicrobial agents with activity against all or the most likely pathogens. Thus initial expectant therapy includes a broad spectrum semisynthetic penicillin (e.g. ampicillin) and an aminoglycoside (e.g. netilmicin). Vancomycin, teicoplanin and cefotaxime may also be used. Supportive therapy consists of temperature control, i.v. administration of fluids, acid-base balance and electrolytes monitoring, seizures control and ventilation. I.V. immunoglobulins, granulocyte and serum transfusion are also used. The G-Golony Stimulating Factor (G-CSF, filgastrim) usage is also reported.

Translated title of the contributionTreatment of group B streptococcus neonatal septicemia
Original languageItalian
Pages (from-to)305-306
Number of pages2
JournalPediatria Medica e Chirurgica
Volume17
Issue number4
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Treatment of group B streptococcus neonatal septicemia'. Together they form a unique fingerprint.

Cite this